Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + diethylstilbestrol
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Docetaxel + diethylstilbestrol is a combination therapy investigated primarily for the treatment of metastatic androgen-independent (castration-resistant) prostate cancer. Docetaxel is a semisynthetic taxane antineoplastic agent that promotes microtubule assembly and stabilizes microtubules by preventing their depolymerization, thereby inhibiting cell division and inducing apoptosis in cancer cells[1][2][6]. Diethylstilbestrol (DES) is a synthetic nonsteroidal estrogen that was historically used for menopausal disorders but has also been studied as an adjunct in prostate cancer due to its hormonal effects[5]. Preclinical studies suggest this combination may have additive or synergistic activity against prostate cancer, with DES potentially inhibiting expression of taxane-resistant tubulin isoforms[3][4]. Clinical trials have shown significant PSA response rates in patients with advanced disease, though toxicity can be substantial[3][4].
- Brand names
- ACT DOCEtaxelTaro-DOCEtaxel
- Other names
- DES
02
Targets
BCL-2 (BCL-2 family)TUBB (Tubulin (alpha and beta subunits))ESR2 (ERβ)ESR1 (ERα)
Beyond the preview
Go deeper on docetaxel + diethylstilbestrol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + diethylstilbestrol.